

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22578-0005US1	Application No. 10/535,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Semple, et al.	
		Filing Date February 15, 2006	Group Art Unit 1626

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,948,786	Sep. 7, 1999	Fujiwara et al.			
	2	6,414,002	Jul. 2, 2002	Cheng et al.			
	3	7,056,942	Jun. 6, 2006	Hildensheim et al.			
	4	7,105,523	Sep. 12, 2006	Stasch et al.			
	5	7,157,466	Jan. 2, 2007	McClure et al.			
	6	7,173,037	Feb. 6, 2007	Alonso-Alija et al.			
	7	7,211,591	May 1, 2007	Tajima et al.			
	8	7,229,991	Jun. 12, 2007	Merla et al.			
	9	7,230,024	Jun. 12, 2007	Carpino et al.			
	10	7,232,823	Jun. 19, 2007	Carpino et al.			
	11	7,241,792	Jul. 10, 2007	Boatman et al.			
	12	2007-0073062	Mar. 29, 2007	Boatman et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	13	EP 1 599 469	Jun. 7, 2006	EPO				
	14	WO2002098864	Dec. 12, 2002	WIPO				
	15	WO2003002544	Jan. 9, 2003	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	16	Guillory, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", in <u>Polymorphism in Pharmaceutical Solids</u> , ed. Harry G. Brittain, Vol. 95, Chap. 5, Marcel Dekker, Inc., New York, 1999, pgs. 183-226.
	17	Karpe, F., et al, "The nicotinic acid receptor—a new mechanism for an old drug", <u>The Lancet</u> , Vol. 363, Jun. 5, 2004, pgs. 1892-1894.
	18	Kubota, N., et al, "Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation", <u>The Journal of Biological Chemistry</u> , Vol. 277, No. 29, Jul. 19, 2002, pgs. 25863-25866.
	19	Li, J., et al, "Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits", Dept. of Cardiovasology, Second Xiangya Hospital, Central South University, Changsha, China, (2007) pgs. 480-484.

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22578-0005US1	Application No. 10/535,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Semple, et al.	
		Filing Date February 15, 2006	Group Art Unit 1626

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	20	Okamoto, Y., et al, "Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice", Circulation - Journal of the American Heart Association, Nov. 26, 2002, pgs. 2767-2770, [retrieved from the Internet on Apr. 24, 2008] http://www.circ.ahajournals.org .
	21	Tunaru, S., et al, "PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect", Nature Medicine, Mar. 2003, Vol. 9, pgs. 352-355 (with "Supplementary Methods" included, one page).
	22	Zhang, et al, "Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A", Biochemical and Biophysical Research Communications, (2005) 334, pgs. 729-732.
	23	Restriction Requirement from copending Application No. 11/601,252 dated May 15, 2007.
	24	Non-Final Office Action from copending Application No. 11/601,252 dated January 8, 2008.
	25	Final Office Action from copending Application No. 11/601,252 dated October 20, 2008.
	26	International Search Report for International Application No. PCT/US2004/035927 (dated Apr. 6, 2005).
	27	International Preliminary Report on Patentability for International Application No. PCT/US2004/035927 (dated Oct. 10, 2005).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	